BioSpark Labs Welcomes Artelon

Artelon®, a leader in dynamic biomaterial innovation, is expanding its Manufacturing and Research and Development activities to BioSpark Labs.

“This expansion to BioSpark enhances our capability to support rapid commercial growth and opens new opportunities for biomaterial innovation. Furthermore, this location connects us to the world-class facilities and collaborative biotech talent in the Georgia Tech ecosystem“ stated Jeff Byrne, the Chief Financial Officer with Artelon.
Artelon is headquartered in Sandy Springs, GA, and manufactures FLEXBAND®, a next-generation dynamic biomaterial used in the surgical repair of tendon and ligament injuries. Artelon’s novel solutions are engineered to enhance the strength and natural motion of healing soft tissues.

For more information, please click on the website link here: https://www.artelon.com/

< Older Post

Newer Post >

September GBG Report Now Available – Federal Funding Insights for Georgia Life Sciences Members

September 11, 2025

Members are invited to join G2G’s Monthly GBG Reporting Service Webinar on September 18, 2025 . The first portion ( 12:00–12:30 PM ET ) is free and open to all, offering a high-level overview of current federal funding trends. The second half ( 12:30–1:00 PM ET ) is a premium consultation available only to Georgia Life Sciences members, offering direct access to G2G’s expert team—who have helped secure over $550 million in non-dilutive government funding since 2007. Register here: https://www.g2gconsulting.com/event/non-dilutive-funding-g2gs-monthly-gbg-reporting-service-webinar-14-3/2025-09-18/ Key opportunities this month include DARPA’s Expedited Research Innovation System for CBRN threat defense technologies, BARDA’s I-CREATE diagnostic funding and VANGUARD biomanufacturing tools development (each offering up to $200,000), NIAID tuberculosis and influenza research units (up to $1.5–$2.5 million annually), DoD’s $4 million Advanced Medical Monitor development through MTEC, and multiple SBIR opportunities for sensors and field-deployable diagnostics (up to $209,575 for Phase I awards). The September GBG report highlights 13 immunology and infectious disease opportunities, 10 cognitive and brain health programs, and several biotechnology and biomanufacturing initiatives across federal agencies including the Army, ARPA-H, BARDA, and NSF. Georgia Life Sciences members can access the complete 29-page report with detailed deadlines and eligibility requirements [insert link or portal instructions here]. GLS members can access the full 29-page report with deadlines and submission details by logging into your member portal.